Bisphosphonate therapy for patients with breast carcinoma: Who to treat and when to stop

Cancer

Volumn 97, Issue 3 SUPPL., 2003, Pages 854-858

  Plunkett, Timothy A ^a   Rubens, Robert D ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

Bisphosphonate therapy; Bone mineral density; Breast carcinoma; Hypercalcemia; Metastatic bone disease

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; PLACEBO; RISEDRONIC ACID; ZOLEDRONIC ACID;

ADVANCED CANCER; BONE METASTASIS; BONE TURNOVER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG TOLERABILITY; EARLY MENOPAUSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MYELOMA; OSTEOLYSIS; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0037302899     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11146     Document Type: Conference Paper

References (15)

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer. 1987;55:61-67.
2. van Holten-Verzantvoort ATM, Kroon HM, Bijovet OLM, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:491-498.
3. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lyric bone metastases. N Engl J Med. 1996;335:1785-1791.
4. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. J Clin Oncol. 1999;17:846-854.
5. Mirels H. Metastatic disease in long bones: a proposed scoring system for diagnosing impending pathologic fractures. Clin Orthopaed Relat Res. 1989;249:256-264.
6. Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer: implications for management. Eur J Cancer. 2000;36:476-482.
7. Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol. 2001;9:3434-3437.
8. Kanis JA, Powles T, Paterson AH, McCloskey EV, Ashley S. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. Bone. 1996;19:663-667.
9. Diel IJ, Solomayer E-F, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357-363.
10. Saarto T, Blomqvist C, Virkkunen P, Elomaa I. Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. J Clin Oncol. 2001;19:10-17.
11. Powles TJ, Paterson S, Kanis JA, et al. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cencer. J Clin Oncol. 2002;20:3219-3224.
12. Kanis JA, McCloskey EV, Powles T, Paterson AHG, Ashley S, Spector T. A high incidence of vertebral fracture in women with breast cancer. Br J Cancer. 1999;79:1179-1181.
13. Saarto T, Blomqvist C, Valimaki M, Makela P, Sarna S, Elomaa I. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients. J Clin Oncol. 1997;15:1341-1347.
14. Powles TJ, McCloskey E, Paterson AH, et al. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer. J Natl Cancer Inst. 1998;90:704-708.
15. Delmas PD, Balena R, Confravreux E, Hardouin C, Hardy P, Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997;15:955-962.